U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H18N2O5S
Molecular Weight 350.39
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENICILLIN V

SMILES

[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC3=CC=CC=C3)C(O)=O

InChI

InChIKey=BPLBGHOLXOTWMN-MBNYWOFBSA-N
InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H18N2O5S
Molecular Weight 350.39
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf

Penicillin V is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Penicillin V has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Penicillin V results from the inhibition of cell wall synthesis and is mediated through Penicillin V binding to penicillin binding proteins (PBPs). Penicillin V is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor. Used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms.

Originator

Curator's Comment: John C. Sheehan, a chemistry professor at Massachusetts Institute of Technology and a former chemist at Merck, synthesized phenoxymethylpenicillin, also known as penicillin V in 1957

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q8XJ01
Gene ID: 990276.0
Gene Symbol: pbpA
Target Organism: Clostridium perfringens (strain 13 / Type A)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15 mg/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
26.3 mg/L
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
35.5 mg/L
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.1 mg/L
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.01 mg × h/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
33.36 mg × h/L
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.94 mg × h/L
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.89 mg × h/L
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.78 h
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.91 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.05 h
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.52 h
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
unknown, oral
PENICILLIN V POTASSIUM serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Disc. AE: Stomach cramps, Nausea...
Other AEs: Diarrhea, Rash...
AEs leading to
discontinuation/dose reduction:
Stomach cramps (0.46%)
Nausea (0.46%)
Other AEs:
Diarrhea (0.8%)
Rash (1.2%)
Abdominal pain (0.8%)
Infection (1.7%)
Headache (1.2%)
Vomiting (2.5%)
Rhinitis (1.2%)
Gastroenteritis (0.4%)
Epistaxis (0.4%)
Ear pain (2.1%)
Cough increased (1.2%)
Nausea (0.8%)
Sources: Page: p.48
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.3A-25S
unhealthy, 16+
n = 117
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 16+
Sex: M+F
Population Size: 117
Sources: Page: p.3A-25S
Disc. AE: Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.7%)
Sources: Page: p.3A-25S
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Disc. AE: Nausea, Taste alteration...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 3, 0.88%)
Taste alteration (grade 3, 0.88%)
Sources: Page: p.341
800 mg 4 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 4 times / day
Route: oral
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 30.0 (6–73)
n = 212
Health Status: unhealthy
Condition: Pharyngotonsillitis caused by group A streptococci
Age Group: 30.0 (6–73)
Sex: M+F
Population Size: 212
Sources:
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 31.0 (3–67)
n = 210
Health Status: unhealthy
Condition: Pharyngotonsillitis caused by group A streptococci
Age Group: 31.0 (3–67)
Sex: M+F
Population Size: 210
Sources:
3 g multiple, oral
Recommended
Dose: 3 g
Route: oral
Route: multiple
Dose: 3 g
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Prophylaxis against bacterial endocarditis
Sources: Page: p.2
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Disc. AE: Rash, Vomiting...
AEs leading to
discontinuation/dose reduction:
Rash (0.57%)
Vomiting (0.57%)
Sources: Page: p.70/306
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Disc. AE: Hypersensitivity reaction, Diarrhea, Clostridium difficile...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (serious|grade 5)
Diarrhea, Clostridium difficile (mild|grade 5)
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Epistaxis 0.4%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Gastroenteritis 0.4%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Nausea 0.46%
Disc. AE
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Stomach cramps 0.46%
Disc. AE
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Abdominal pain 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Diarrhea 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Nausea 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Cough increased 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Headache 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Rash 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Rhinitis 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Infection 1.7%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Ear pain 2.1%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Vomiting 2.5%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Abdominal pain 1.7%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.3A-25S
unhealthy, 16+
n = 117
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 16+
Sex: M+F
Population Size: 117
Sources: Page: p.3A-25S
Nausea grade 3, 0.88%
Disc. AE
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Taste alteration grade 3, 0.88%
Disc. AE
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Rash 0.57%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Vomiting 0.57%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Diarrhea, Clostridium difficile mild|grade 5
Disc. AE
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Hypersensitivity reaction serious|grade 5
Disc. AE
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[The antiviral activity of the antibiotics beromycin and carminomycin].
1974 Feb
[Immune hemolytic anemia and thrombocytopenia after peroral therapy with a penicillin derivative (phenoxymethylpenicillin)].
1977
Assessment of the "E' book as a tool for drug monitoring.
1981 Mar
[Leukocytoclastic vasculitis due to drug allergy presenting as generalized pustular exanthema].
1981 Sep
Effect of drugs influencing synthesis of prostaglandins on haloperidol-induced catalepsy in rats.
1984 Jul-Sep
Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy.
1990 Nov
Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V.
2005 Dec
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.
2006
Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin.
2006
Clinical practice. Antibiotic allergy.
2006 Feb 9
HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins.
2006 Mar 20
[Express determination of beta-lactam antibiotics in biological matter with potentiometric sensors].
2007
[The microbiology of peritonsillar abscesses].
2007
Hypersensitivity to penicillin V with good tolerance to other beta-lactams.
2007
Meningomylocele: An update.
2007 Apr
Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers.
2007 Dec
Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin.
2007 Jul
Dishing the dirt on asthma: What we can learn from poor hygiene.
2007 Jun
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.
2007 Jun
Leukocyte counts in urine reflect the risk of concomitant sepsis in bacteriuric infants: a retrospective cohort study.
2007 Jun 13
Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients.
2007 Mar
Evaluation of phenoxymethylpenicillin treatment of acute otitis media in children aged 2-16.
2007 Sep
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.
2008 Aug
Effects of treatment with antimicrobial agents on the human colonic microflora.
2008 Dec
[Summary of the practice guideline 'Sore throat' (second revision) from the Dutch College of General Practitioners].
2008 Feb 23
Antimicrobial susceptibility of periodontopathogenic bacteria.
2008 May
A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya.
2008 Nov 18
Drug use in children: cohort study in three European countries.
2008 Nov 24
Antistreptococcal treatment of guttate psoriasis: a controlled study.
2008 Sep
Treatment of Lyme borreliosis.
2009
Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group A beta-Hemolytic Streptococcus pharyngitis in Children.
2009
Treatment and prevention of Lyme disease.
2009
Trends in number of consultations and antibiotic prescriptions for respiratory tract infections between 1999 and 2005 in primary healthcare in Kalmar County, Southern Sweden.
2009
SDRIFE (baboon syndrome) induced by penicillin.
2009 Apr
The role of phenoxymethylpenicillin, amoxicillin, metronidazole and clindamycin in the management of acute dentoalveolar abscesses--a review.
2009 Apr 11
Antibiotic prescribing in paediatric populations: a comparison between Viareggio, Italy and Funen, Denmark.
2009 Aug
Challenges of cellulitis in a lymphedematous extremity: a case report.
2009 Dec 22
Hypersensitivity reactions to penicillins: studies in a group of patients with negative benzylpenicillin G skin test.
2009 Jun
Specific IgG antibodies in sera in patients with penicillin allergy.
2009 Jun
Acute tonsillopharyngitis in a family practice in Mostar, Bosnia and Herzegovina.
2009 Mar
[An exceptional component C3 deficiency revealed by serum protein electrophoresis].
2009 Nov-Dec
Antibiotic prescribing practices by dentists: a review.
2010 Jul 21
A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis.
2010 Mar
Decreased Streptococcus pneumoniae susceptibility to oral antibiotics among children in rural Vietnam: a community study.
2010 Mar 31
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.
2010 Nov
How are antibacterials used in nursing homes? Results from a point-prevalence prescription study in 44 Norwegian nursing homes.
2010 Oct
Prevalence of Group A b-Hemolytic Streptococcus Among Children with Tonsillopharyngitis in Kyrgyzstan: The Difficulty of Diagnostics and Therapy.
2010 Oct 13
Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells.
2012 Aug 1
Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity.
2012 Feb
Synthesis of novel hapten and production of generic monoclonal antibody for immunoassay of penicillins residues in milk.
2013
Patents

Sample Use Guides

Usual Adult Dose for Bacterial Infection Mild to moderate infections: 125 to 500 mg orally every 6 to 8 hours
Route of Administration: Oral
Penicillin V inhibited Staphylococcus aureus in human THP-1 macrophages (intracellular) with MIC90 of 0.015 mg/L
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:05:31 GMT 2023
Edited
by admin
on Sat Dec 16 18:05:31 GMT 2023
Record UNII
Z61I075U2W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENICILLIN V
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS  
USAN  
Official Name English
PENICILLIN V [HSDB]
Common Name English
VEBECILLIN
Common Name English
phenoxymethylpenicillin [INN]
Common Name English
PHENOXYMETHYLPENICILLIN [WHO-IP]
Common Name English
PENICILLIN PHENOXYMETHYL
Common Name English
PENICILLIN V [USP-RS]
Common Name English
PENICILLIN V [ORANGE BOOK]
Common Name English
PHENOXYMETHYLPENICILLIN
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
DISTAQUAINE V
Common Name English
PHENOXYMETHYLPENICILLIN [MART.]
Common Name English
PHENOXYMETHYLPENICILLIN [EP MONOGRAPH]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENOXYACETYL)AMINO)-, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-
Common Name English
PENICILLIN V [MI]
Common Name English
Phenoxymethylpenicillin [WHO-DD]
Common Name English
PENICILLIN V [USP MONOGRAPH]
Common Name English
PHENOXYMETHYLPENICILLINUM [WHO-IP LATIN]
Common Name English
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Systematic Name English
V-CILLIN
Brand Name English
PENICILLIN V [USAN]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01CE02
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
WHO-ATC J01CE02
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
NDF-RT N0000175497
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
WHO-ATC J01CE10
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
CFR 21 CFR 520.1696C
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
NCI_THESAURUS C1500
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
CFR 21 CFR 520.1696D
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
LIVERTOX NBK547993
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID3023429
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
SMS_ID
100000090361
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
RXCUI
7984
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL615
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
ECHA (EC/EINECS)
201-722-0
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
EVMPD
SUB09779MIG
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
PUBCHEM
6869
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
MESH
D010404
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
LACTMED
Penicillin V
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
RS_ITEM_NUM
1504489
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
FDA UNII
Z61I075U2W
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
HSDB
6314
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
DRUG BANK
DB00417
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
WIKIPEDIA
PHENOXYMETHYLPENICILLIN
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
CAS
87-08-1
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
CHEBI
27446
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
NCI_THESAURUS
C62064
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
DRUG CENTRAL
2083
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
DAILYMED
Z61I075U2W
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
MERCK INDEX
m8479
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
PENICILLIN V
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY Description: A white, fine crystalline powder. Solubility: Soluble in 1700 parts of water and in 7 parts of ethanol (~750 g/l) TS. Category: Antibiotic. Storage: Phenoxymethylpenicillin should be kept in a tightly closed container, protected from light. Additional information: Even in the absence of light, Phenoxymethylpenicillin is gradually degraded on exposure to a humidatmosphere, the decomposition being faster at higher temperatures. Definition: Phenoxymethylpenicillin contains not less than 95.0% and not more than 102.0% of C16H18N2O5S, calculated withreference to the anydrous substance.
INN
518
Created by admin on Sat Dec 16 18:05:34 GMT 2023 , Edited by admin on Sat Dec 16 18:05:34 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY